Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00162448 | A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators | PHASE1 | COMPLETED | 36 | — | — | Jan 1, 2005 | - | Aug 20, 2008 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | - |
| A2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-394136 | DRUG | Oral Solution, Oral, 100 mg, Single dose, 1 day. |
| Placebo | DRUG | Oral Solution, Oral, 0 mg, Single dose, 1 day. |
Inclusion Criteria: * Patients with dual-chamber pacemakers or defibrillators Exclusion Criteria: * Recent acute ischemic events * Recent atrial or ventricular arrhythmias * Uncompensated heart failure * Amiodarone use within last year * Women of childbearing potential * QTc \<430 msec males * QT...